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Radiotherapy remains an important treatment modality in nearly two thirds of all cancers,
including the primary curative or palliative treatment of breast cancer. Unfortunately,
largely due to tumor heterogeneity, tumor radiotherapy response rates can vary
significantly, even between patients diagnosed with the same tumor type. Although in
recent years significant technological advances have been made in the way radiation can
be precisely delivered to tumors, it is proving more difficult to personalize radiotherapy
regimens based on cancer biology. Biomarkers that provide prognostic or predictive
information regarding a tumor’s intrinsic radiosensitivity or its response to treatment could
prove valuable in helping to personalize radiation dosing, enabling clinicians to make
decisions between different treatment options whilst avoiding radiation-induced toxicity
in patients unlikely to gain therapeutic benefit. Studies have investigated numerous ways
in which both patient and tumor radiosensitivities can be assessed. Tumor molecular
profiling has been used to develop radiosensitivity gene signatures, while the assessment
of specific intracellular or secreted proteins, including circulating tumor cells, exosomes
and DNA, has been performed to identify prognostic or predictive biomarkers of radiation
response. Finally, the investigation of biomarkers related to radiation-induced toxicity
could provide another means by which radiotherapy could become personalized. In
this review, we discuss studies that have used these methods to identify or develop
prognostic/predictive signatures of radiosensitivity, and how such assays could be used
in the future as a means of providing personalized radiotherapy.
Keywords: biomarkers of radiosensitivity, breast cancer, precision medicine, molecular signatures of
radiosensitivity, biomarkers of radiation-induced toxicity
RADIOTHERAPY IN BREAST CANCER TREATMENT
In 2018 it was estimated that ∼18 million new cancer cases and 10 million cancer-related deaths
occurred worldwide (1). If current trends in global population growth continue, combined with
the effects of an aging population, these figures are predicted to increase to 20 million new cases
and 13 million deaths per year by 2030 (2). Breast cancer (BC) is the most common female cancer,
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with ∼2 million new cases and 0.7 million cancer-related deaths
occurring per year (1). Despite the multitude of advances made
in both the surgical and systemic treatment of cancer patients,
radiotherapy (RT) has a key role in the management of nearly
two thirds of all cancers (3).
RT is commonly given to BC patients after surgery. These
adjuvant RT treatment plans typically involve the delivery of
radiation to the tumor in multiple fractions over a period of
several weeks. The most common adjuvant RT fractionation
regimen following breast-conserving surgery is 25 fractions
of 2Gy over a 5 week period, or hypofractionated regimens
consisting of a total of 40Gy delivered in 15 fractions over
3 weeks (4). An external beam boost to the tumor bed can
also be employed following whole-breast RT or integrated
simultaneously with whole-breast irradiation (5) for invasive
BCs which have a high risk of local recurrence. This boost
procedure typically involves either 10Gy in 5 fractions or
16Gy in 8 fractions (6, 7), both delivered over the course of
1 week, or a radiobiologically equivalent dose such as 12Gy
in 4 fractions (8). Local recurrences occur most commonly
at the original site of the primary tumor due to remaining
microscopic tumor cells left following surgery; the objective of
adjuvant and boost RT is to eradicate these tumor cells (7, 9).
Accelerated partial breast irradiation (APBI) can be considered as
an alternative treatment approach to conventional external beam
RT or exclusive hormonal therapy which may be particularly
useful for patients with a low-risk of local tumor recurrence or
for elderly patients. APBI allows the delivery of higher radiation
doses in the area of the tumor bed whilst reducing the dose
received by normal breast tissue and adjacent organs at risk.
Shorter treatment times and acceptable acute toxicity rates can
improve patient quality of life whilst also reducing the total cost
of treatment (10–14). Linear accelerators are the most commonly
used devices for delivering external beam radiation to patients.
In recent years, these machines have undergone significant
technology-driven improvements that have culminated in the
generation of modern radiation-delivery techniques such as
intensity-modulated RT and image-guided RT approaches, which
are designed to allow highly conformal and precise distribution
of radiation to the tumor. Radiation delivery methods such
as “dose painting by numbers” or sculpturing are becoming
achievable through the use of these machines, meaning that
identified subvolumes can be targeted specifically, limiting the
radiation dose received by the nearby normal tissues (15).
Although these current radiation planning techniques are largely
based on advanced imaging to identify the gross tumor volume,
the identification of a biological target volume based on the
underlying tumor biology could lead to the development of a
more personalized radiation treatment plan.
Of patients diagnosed with BC in England between 2013
and 2014, 63% received curative or palliative RT as part of
their primary treatment (16). The Oxford overview shows that
adjuvant RT halves the 10-year first risk of recurrence (most
of which are local breast recurrences) after breast-conserving
surgery and systemic therapy in all risk categories (9) and
improves survival in lymph node positive patients receiving
adjuvant systemic therapy (17). Studies have suggested that RT
can benefit up to 83% of BC patients (18) and that breast-
conserving surgery followed by whole-breast RT can provide
local control and survival rates equivalent to mastectomy (19–
21). These results, combined with the advantages of improved
cosmetic outcomes and reduced side effects, have made the
incorporation of RT into BC treatment standard practice for a
large proportion of patients. Unfortunately, not all BC patients
gain therapeutic benefit from RT. Although overall 5-year
survival rates after RT are ∼80%, it is estimated that 30% of
these patients will develop local recurrences or metastatic disease,
the majority of whom will die within 5 years (22). Additionally,
others in the neoadjuvant and palliative settings may only
experience an initial partial response or may not respond at all.
Side effects, which can affect a patient’s quality of life, can also
occur with RT.
A variety of imaging approaches for measuring tumor
response to RT during or after treatment have been developed;
these typically analyse how often and by how much a tumor
shrinks anatomically. The RECIST (Response Evaluation Criteria
in Solid Tumors) criteria have been widely adopted and are
commonly used in oncology clinical trials. This categorizes the
tumor response into complete (disappearance of tumor lesions
for at least 4 weeks), partial (tumor diameter reduction of at least
30% for at least 4 weeks), stable (neither progressive disease nor
partial response) or progressive (tumor diameter increase of at
least 20%). Imaging techniques used to measure these changes
in tumor size include X-ray, X-ray computed tomography,
magnetic resonance imaging and positron emission tomography
(23). However, as many of these techniques measure changes in
tumor size alone to assess response to treatment, they ignore
the underlying biology that drives the response to radiation.
Additionally, analyzing changes in tumor size is a measurable
clinical outcome that is seen only towards the end or after the
treatment has finished, with patients who fail to respond to
treatment initially going undetected. This delay may contribute
to tumor progression, impact long-term survival and ultimately
delay the initiation of an alternative treatment strategy. Non-
responding patients will also be at risk of developing RT-induced
side effects for no therapeutic gain. Despite the significant
evidence that RT can benefit BC patients as a whole, there are
still no clinically validated biomarkers that can be used to predict
whether neoadjuvant/adjuvant RT will improve outcomes for
individual patients.
PRECISION MEDICINE, PROGNOSTIC
AND PREDICTIVE BIOMARKERS
Precision medicine is defined as the incorporation of
disease biomarkers, molecular signatures and phenotypes
in combination with patient lifestyle and environment into the
prevention, investigation and treatment of diseases (24). Using
these criteria, patients can be classified into cohorts according
to differences in disease susceptibility, prognosis and likely
treatment response rates. To improve clinical outcomes, this type
of information can be used to select patients that may require
more aggressive treatments and those that are most likely to
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benefit from specific treatments (25). Genomic instability is a key
feature of cancer that is characterized by genetic and epigenetic
heterogeneity (26–28); it is therefore not surprising that patients
diagnosed with the same cancer type vary in prognosis and in
their responses to treatment. As we improve our understanding
of the fundamental processes that control carcinogenesis and
pathogenesis, precision medicine will become more and more
important in the management of cancer patients. An era of
personalized cancer medicine, in which biomarkers can be
used to tailor treatment to each specific patient, is a major goal
in oncology.
Biomarkers can be defined as characteristics which can be
evaluated and measured as indicators of normal biological
processes, pathogenesis or response to therapy (29). Cancer
biomarkers may be diagnostic, prognostic, predictive, or used
to monitor treatment responses. Prognostic biomarkers provide
information about a patient’s overall cancer outcome, irrespective
of therapy. They can identify high-risk patients who may benefit
from more aggressive treatments but provide no information on
which patients will most likely derive a clinical benefit from a
specific therapy. Conversely, predictive biomarkers can indicate
the probability of a patient gaining a therapeutic benefit from a
specific treatment (30–32). These fundamental prognostic and
predictive biomarker concepts have been integrated into the
precision medicine initiative.
BC radiomics, an emerging field in precision medicine, is
the process of extracting quantitative information from medical
images to influence patient treatment. This concept assumes
that extracted imaging data are the result of biological processes
occurring at a genetic and molecular level, and are therefore
associated with the genotypic and phenotypic characteristics
of the tumor (33). Radiomic features have been correlated
with BC clinical data including stage, lymph node involvement
and hormone receptor status (34), and also have the ability
to discriminate between malignant and benign lesions (35).
While radiomics has the potential to contribute to BC precision
medicine in the future, BCmolecular classification systems based
on microarray gene expression analysis are currently being used
clinically. These classification systems have identified several
intrinsic BC molecular subtypes which have been shown to differ
in treatment responses and predict disease-free survival and
overall survival (36–39). Unfortunately, microarray analysis or
genome sequencing for individual patients is cost-prohibitive
for routine clinical use. To overcome this issue, studies have
investigated the potential utility of using smaller gene sets to
stratify BC patients, providing prognostic and/or predictive
information which can be employed by clinicians to guide the
use of adjuvant chemotherapy or endocrine therapy (40). These
clinically-available tests include the breast cancer index (41),
Endopredict (42), the Oncotype DX 21-gene recurrence score
(43), the BreastOncPx 14-gene distant metastasis signature (44),
and theMammaPrint 70-gene prognosis signature (45). Finally, a
50-gene signature called PAM50 (now commercialized under the
name Prosigna) has improved the ability to predict recurrence
of estrogen receptor+/lymph node− BC patients compared to
models using only clinical variables (46, 47). Although these
clinically validated genetic tests have made significant changes
in the way patients are selected for receiving chemotherapy or
endocrine therapy, RT treatment plans still rely upon historically
standardized, one-size-fits-all therapeutic approaches.
A move toward more personalized RT treatment, tailored to
individual risk and tumor biology, would help improve patient
outcomes (48). Many factors are known to influence a tumor’s
response to irradiation, including total dose, fractionation, tumor
doubling time, hypoxia and intrinsic radiosensitivity. If RT is
to become part of the precision medicine initiative, we need to
identify clinically-validated biomarkers that can predict response
to RT before starting treatment or biomarkers that can help
clinicians assess a tumor’s response to RT during treatment
(49). Currently there are no sufficiently validated biomarkers
of radiosensitivity for routine application in the clinic (49).
These assays/biomarkers might allow the tailoring of radiation
dose regimens to individual patients based on tumor biology
or the prediction of the risk of localized tissue toxicity. Patients
unlikely to benefit from RT could be spared radiation-induced
toxicities and associated co-morbidities, whilst allowing more
effective therapies to be instigated at an earlier stage of the
treatment process (Figure 1). As discussed above, molecular
signatures have been developed that enable clinicians to more
individually tailor systemic therapies for patients with BC. Slower
progress is being made to develop tools to predict RT response;
in part this is due to radiation oncology vendors not having the
financial capacity to support genomic-orientated collaborations
with radiation oncology investigators (50). Nonetheless, much
work has been performed to try and develop such biomarkers.
The aim of this review is to highlight recent developments in this
exciting yet under-researched field.
MOLECULAR SIGNATURES OF
RADIOSENSITIVITY
Intrinsic Subtypes
Gene expression profiling and histopathological classification
using the expression of estrogen receptor (ER), progesterone
receptor (PgR) and human epidermal growth factor receptor 2
(HER2) can be used to classify BC into different subtypes. These
subtypes can be broadly categorized into luminal, normal-like,
HER2-overexpressing and triple negative breast cancer (TNBC)
(36–39, 51). Gene expression profiling can stratify BC subtypes
to a greater degree than histological assessment; however, as
previously mentioned, this is often not feasible for use with
large scale patient populations due to financial constraints (52).
Both classification methods have confirmed the heterogeneous
nature of BC which can lead to substantial differences in
biology, pathogenesis, treatment response and patient outcome
(39, 53, 54). Luminal subtypes (which correspond to ER+
BC) are associated with a more favorable prognosis, whereas
HER2-overexpressing and TNBC subtypes are associated with
significantly worse recurrence-free survival and overall survival.
BC subtyping has also been investigated for its use in
predicting response to RT. The major advantage of using these
subtyping markers in the selection of patients for RT is that
testing for these markers using biopsy samples is now mandatory
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FIGURE 1 | Precision medicine and radiotherapy. Patients could be stratified into different cohorts based on predicted intrinsic radiosensitivity and risk of toxicity.
On-treatment monitoring may provide information on response to treatment, enabling adaptive changes to a patient’s treatment to be made if necessary.
Post-treatment biomarkers could be used to assess for evidence of toxicity, tumor recurrence or the development of metastatic disease.
in the clinics, as they are used for selecting patients for hormonal
or targeted therapies. In vitro studies using BC cell lines have
shown that individual subtypes exhibit differential inherent
sensitivities to radiation (55). Multiple clinical analyses have
also shown that subtype is related to radiosensitivity; one large
study reported that local recurrence for invasive BC treated
with breast-conserving surgery followed by RT was 0.8% for
luminal A, 1.5% for luminal B, 8.4% for HER2-overexpressing
and 7.1% for TNBC (56). HER2-overexpressing and TNBC have
also been associated with an increased risk of local recurrence and
distant metastasis in combination with reduced overall survival
in patients treated with post-mastectomy RT or RT alone (56–
58). Improved overall survival after post-mastectomy RT has
also been identified in ER+/ PgR+/HER2− patients, whereas
no significant overall survival improvement was seen following
the same treatment in ER−/ PgR−/HER2+ patients (58). Similar
results were observed when using the Oncotype DX recurrence
score to predict overall survival following post-mastectomy RT;
this study suggested that low-risk patients, as determined by
low OncotypeDX recurrence scores, had significantly improved
overall survival following post-mastectomy RT compared to
those low-risk patients that did not receive this treatment. In
comparison, post-mastectomy RT was not of significant benefit
to intermediate and high-risk patients. The authors suggested
that OncotypeDX recurrence score may be a predictor of
survival benefit from post-mastectomy RT (59). Furthermore,
improved overall survival has been documented in patients with
ER+/ PgR+/HER2− tumor who received post-mastectomy RT
when compared with those who received no RT (58). This
suggests that RT is particularly effective for breast cancers of the
luminal phenotype.
Pan-Cancer Genomic Signatures
The first pan-cancer genomic radiosensitivity signature was
developed using 35 cancer cell lines from the National Cancer
Institute-60 (NCI-60) panel (60). Torres-Roca et al. (60) used
gene expression data combined with the survival fraction of cells
that received a dose of 2Gy (SF2), an accepted experimental
measure of cellular radiosensitivity, to develop a radiation
classifier that could predict inherent radiosensitivity. Their
results showed that the classifier successfully predicted SF2 values
in 22 of 35 NCI-60 cell lines. The authors then went on to identify
three novel genes (RbAp48, RGS19, and R5PIA) whose expression
was correlated with radiation sensitivity. These results were the
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first to show that gene expression profiles had the potential to
predict radiation sensitivity and that genomics could be used to
identify novel radiosensitivity molecular markers. Unfortunately,
subsequent studies have failed to reproduce these in vitro results
using modern gene expression techniques; therefore, the validity
of this signatures use in cell lines remains open to debate (61).
This pan-cancer genomic radiosensitivity signature has since
been developed by the same group to include biological variables
such as tissue of origin, p53 and ras status, known influencers
of radiosensitivity. Using SF2 values from 48 cancer cell lines
from the NCI-60 panel, gene expression analysis was performed
to identify a 10 gene signature associated with intrinsic
radiosensitivity (AR, cJun, STAT1, PKC, RelA, cABL, SUMO1,
CDK1, HDAC1, and IRF1). These 10 genes are associated with
specific pathways that included cell cycle, DNA damage response,
histone deacetylation, proliferation and apoptosis. These results
were used to produce a radiosensitivity index (RSI), whereby
lower RSI correlates with greater radiosensitivity (62). The RSI
has been used in clinical studies; these have shown the signature
to be disease-site independent, predicting clinical outcomes in
esophageal, rectal, head and neck, prostate, pancreas, colon,
glioblastoma and non-small cell lung cancer patients following
RT (62–66). However, some of these results were obtained from
pilot studies which had low patient numbers, whereas others
did not compare the results with non-RT treated controls.
The RSI has also been evaluated in 2 independent BC patient
cohorts. Results indicated that RT-treated patients classified as
radiosensitive by RSI had improved recurrence-free survival or
distant metastasis-free survival at 5 years, but there was no
difference in recurrence-free survival or distant metastasis-free
survival between radiosensitive and radioresistant patients in
those not treated with RT. The authors suggested that RSI is
RT-specific, because it was not prognostic for patients treated
with surgery alone, but importantly can be used as a predictive
signature of RT benefit. Furthermore, they demonstrated that
the impact of RSI was affected by ER status, with RSI-classified
radiosensitive patients having greater distant metastasis-free
survival in ER+ patients (67). RSI has also been integrated with
BC molecular subtyping to predict local recurrence; Torres-Roca
et al. (68) showed that although RSI did not uniformly predict for
local recurrence, it was able to identify a subpopulation of TNBC
that had high RSI scores which were classified as radioresistant
with the highest risk of local recurrence. They also illustrated that
RSI could identify a luminal radioresistant subpopulation that
would benefit from radiation dose escalation. They concluded
that the combined use of RSI andmolecular subtyping could help
guide the selection of patients for RT treatment in BC (68).
In an attempt to tailor radiation doses across differing BC
subtypes, researchers have integrated the RSI with the linear
quadratic model to derive a genomic-adjusted radiation dose
(GARD); this aimed to predict which tumors would gain
an enhanced therapeutic effect from RT. GARD values were
calculated for over 800 tumor samples using data from the
prospective, observational Total Cancer Care cohort. The results
demonstrated that there was a wide range of GARD values
within tumor types and that GARD values could independently
predict clinical outcome in lung, pancreatic, glioblastoma and BC
patients (69). The limitations of this study included the failure
to evaluate the prognostic potential of GARD (no data were
evaluated for patients that did not receive RT) and a lack of
external validation. However, this GARD-based clinical model
could allow for RT personalisation based on radiation dose
tailored to tumor radiosensitivity and may provide a means to
develop genomically-guided RT-based clinical trials.
A similar approach which used the same NCI-60 cell line
panel was undertaken to identify not only genes whose expression
profiles were related to intrinsic radiosensitivity, but also genes
whose expression changed following radiation treatment and
were associated with post-radiation survival. Changes in gene
expression induced by radiation were found to be similar between
different tumor types and were also associated with p53 status.
The authors suggested that there was possibly a conserved
set of genes responsible for a specific radiation response (70).
However, this work contradicts a more comprehensive study
that profiled the radiation response of over 500 cell lines which
showed sensitivity to radiation was characterized by significant
genetic variation within and between cell line lineages. As well as
identifying genes whose expression was associated with response,
they also identified somatic copy number alterations and gene
mutations that correlated with post-radiation survival (71).
In addition to radiation-induced gene response signatures,
other groups have looked at signatures that may predict response
to radiation treatment for a range of different cancer types. These
gene expression profiles include hypoxia-related signatures (72–
74), cell cycle and DNA damage gene-related signatures (75, 76),
along with signatures predicting response to radiosensitising
drugs (77, 78). As with many of the other in vitro derived
signatures, none of these has thus far withstood stringent
external validation and therefore have yet to be translated into
clinical practice.
Breast Cancer Specific Genomic
Signatures
With a technique similar to that employed to produce the
RSI, a different study used only BC cell lines to develop a
BC specific radiation sensitivity signature (RSS) (79). Their
aim was to produce a gene signature that could predict the
radiation response of BC patients and allow the identification
of patients with tumors refractive to conventional RT regimens.
To derive their gene signature, intrinsic radiosensitivity was
correlated with gene expression using SF2 values from a
panel of 16 BC cell lines. Interestingly, Speers et al. (79)
found no association between intrinsic radiosensitivity of the
BC cell lines and subtype classification, contradicting findings
from previous publications. A 51 gene signature, enriched for
pathways involved in DNA damage response and cell cycle, was
developed from their results. Validation of this gene signature,
the most promising to date, was performed in two independent
clinical BC datasets in which patients had been treated with
breast-conserving surgery and RT. The results showed that the
RSS could provide information on which patients were likely
to respond poorly to standard RT regimens (79). However, as
all patients in the studied cohorts received standard RT, the 51
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gene signature could not be validated for its predictive potential.
This RSS has subsequently been marketed as RadiotypeDX and
is regarded as having potentially similar applications to that of
OncotypeDX, which is used for selecting the most appropriate
systemic therapies for BC patients. RadiotypeDX is currently
undergoing external validation, using tissue and clinical data
from a randomized controlled trial evaluating post-operative
RT after breast-conserving surgery in patients with early BC,
who received appropriate adjuvant systemic therapy according
to ER status (80). Although the results are yet to be published,
these types of trials, as well as prospective randomized trials
or “prospective retrospective” analyses from phase III trials, are
essential in order to show that these kinds of signatures have
clinical applications and that they could be integrated into clinical
practice (81).
More recently a refined version of RadiotypeDX (Adjuvant
Radiotherapy Intensification Classifier [ARTIC]) has been
validated in a Swedish Conservation trial in which patients were
randomized to post-operative whole-breast RT or no RT (82).
Of note, a limited number of patients in this trial received
systemic therapy. ARTIC was found to be highly prognostic
for loco-regional recurrence and predictive of benefit from RT.
Patients who had a low ARTIC score derived a substantial benefit
from RT; in contrast, patients with high ARTIC scores had
less benefit from RT. The authors recognized the requirement
to validate ARTIC within a trial of patients treated by breast-
conserving therapy, systemic therapy +/– post-operative whole-
breast irradiation.
A gene profile called DBCG-RT, predictive for therapeutic
benefit from post-mastectomy RT and prognostic for
locoregional control, was developed by the Danish Breast
Cancer Cooperative Group and has been independently
validated (83). The DBCG-RT gene profile can divide patients
into those with a high- and low-risk of local recurrence and
can identify a subcategory of low-risk patients who obtain no
additional benefit from RT. A correlation between patients that
were at an increased risk of developing local recurrence and
non-luminal, ER− tumors (basal and HER2-overexpressing) was
observed, while the low local recurrence risk group correlated
with the luminal A subtype. These findings indicate that intrinsic
subtyping and the DBCG-RT profile can identify the same tumor
types and their responses to RT treatment.
Others have attempted to develop specific radiation signatures
for BC that distinguish patients who require treatment
intensification, for whom traditional therapies (surgery,
chemotherapy and RT) are inadequate. Gene analysis has been
conducted on early stage BC patients, all treated with RT after
surgery, to try and distinguish gene signatures prognostic of
local recurrence in patients treated with radiation. A radiation
signature consisting of 81 genes outperformed pathologic and
clinical characteristics for predicting local recurrence (84). A
similar study performed gene expression microarray profiling
to identify differentially expressed genes between tumors from
patients who developed local recurrence after breast-conserving
surgery and radiation, and patients who did not; Kreike et al.
(85) derived a 111 gene signature, enriched for cell proliferation,
which was independently associated with local recurrence.
Unfortunately, both of these signatures failed external validation.
The Early Breast Cancer Trialists’ Collaborative Group meta-
analysis suggested that most early stage BC patients treated
with breast-conserving surgery are cured of their disease with
both surgery and endocrine therapy alone, without the need
for RT (9). Studies have also suggested that RT may be
omitted in selected elderly patients with low-risk disease (86).
RT omission after breast-conserving surgery has also been
explored in several randomized phase III trials; unfortunately,
heterogeneous eligibility criteria across the trials has resulted
in differing results with confounding interpretations (87).
These types of studies have led to an increased interest
in the development of radiation omission signatures specific
for BC, whereby low-risk patients can be spared RT. An
omission signature has yet to be developed; however, different
groups are attempting to validate a variety of previously
described molecular classifiers for this purpose. Trials are
ongoing to assess the potential of OncotypeDx (IDEA trial),
Prosigna (PRECISION trial), IHC (LUMINA trial), and IHC4
(PRIMETIME trial) scores as stratification methods for radiation
omission (81).
Barriers to Clinical Adoption of Molecular
Signatures
Although many molecular signatures have been developed to
predict a tumor’s response to radiation, most have failed external
validation and, as a result, none have gained approval for clinical
use. In part, as indicated earlier, the barriers are the high
costs of academic-industry collaborations and in part scientific
(50). Unfortunately, the gene profiles derived from the studies
outlined in this review show little similarity to each other, which
suggests that the methods used to produce the signatures may
influence which genes and pathways are selected. Like many
other cancers, BC is a complex heterogenous disease; differences
in pathway activation can lead to different drivers of oncogenesis,
even within the same subtype. These significant differences will
influence how each tumor reacts to RT; it is possible that gene
signatures are unable to account for the complexity of a tumor’s
radiation response. These issues are likely to bemore pronounced
in profiles derived from cell lines, as these are clonal populations
that cannot account for tumor heterogeneity and the effects of
the tumor microenvironment. Validation of the signatures using
clinical trial data is also complicated; variations between trials
in terms of the radiation treatment regimens used, inclusion
of different patient subtypes and inconsistencies between the
numbers of treated and control patients included in the studies
makes the generation of meaningful data and rigid signature
validation challenging. The methods used for RNA extraction
and subsequent gene expression analysis can also differ between
the original studies which developed the profiles and the clinical
trials in which they are being validated. These issues are specific
for gene signature validation; there are also more general hurdles
that must be overcome if lab-based research is to be successfully
translated into a clinically applicable test. These include the
development of standard operating procedures and making tests
cost effective and easy to use, while also providing evidence that
they can improve upon standard practices already in place in
the clinics. The combination of these gene signature specific and
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general issues are factors that are currently contributing to their
lack of clinical translation and use in the clinic.
GENE MUTATIONS, mRNA AND
INTRACELLULAR PROTEIN MARKERS
Several studies have looked at individual biomarkers, rather
than cohorts of genes, for their potential to correlate with a
tumor’s response to RT. In BC, expression levels of Holliday
junction recognition protein mRNA can be prognostic for
disease-free survival and overall survival, thereby predicting
patient sensitivity to RT (88). High cytoplasmic expression of
peroxiredoxin-I has also been shown to correlate with increased
local recurrence after RT (89). Proteasome (prosome, macropain)
26S subunit, non-ATPase, 9 (PSMD9) is another protein whose
elevated expression was associated with increased incidence of
local recurrence in a cohort of patients that received adjuvant RT,
but not in those that did not receive RT; the authors concluded
that this protein might therefore be a predictive biomarker for
RT response (52).
The BRCA1/2 genes are part of the granin gene family
and function as tumor suppressors; they play critical roles
in maintaining genome stability through controlling pathways
involved in DNA damage response/repair, cell cycle and
transcription (90). Previous studies have shown that BRCA1/2
gene deregulation is associated with BC carcinogenesis (91),
with germline BRCA1/2 mutations accounting for up to 10%
of all cases (92). Inherited BRCA1/2 mutations are estimated
to increase the risk of BC by to 84% (93–95). These tumors
exhibit ineffective homologous recombination DNA repair,
causing an accumulation of genetic mutations, which can drive
carcinogenesis. Although tumors deficient in a DNA repair
mechanism may be expected to exhibit radiation sensitivity,
they are instead thought to rely upon alternative DNA repair
mechanisms that are more effective at repairing radiation-
induced DNA damage. PARP enzymes play a key role in
the repair of DNA single-strand breaks through the repair
of base excisions, a process normally performed by error-
free homologous recombination (96). The inhibition of PARPs
can result in the accumulation of DNA single-strand breaks,
leading to the generation of double-strand breaks at replication
forks. Double-strand breaks are usually repaired by error-
free homologous recombination, a process that is inhibited
in BRCA1/2 mutated tumors; these double-strand breaks can
lead to apoptosis of cancer cells within the tumor. The PARP
enzyme inhibitor olaparib is currently undergoing trials to assess
its clinical usefulness and cost effectiveness in the treatment
of BRCA1/2 mutated HER2− metastatic BC patients following
chemotherapy (97). This drug has previously gained clinical
approval for use in patients with recurrent, platinum-sensitive,
BRCA1/2 mutated ovarian cancers (98). Furthermore, the
small molecular PARP inhibitor niraparib has been shown to
radiosensitise a variety of human xenograft tumors, including
the triple-negative MDA-MB-231 human BC cell line (99). It
has therefore been suggested that BRCA status could be a useful
biomarker for stratifying patients for the use of PARP inhibitors
in combination with RT.
BLOOD-ASSOCIATED BIOMARKERS OF
TUMOR RADIOSENSITIVITY
The identification of circulating prognostic or predictive
biomarkers in the blood has advantages over tissue-based
approaches as it is non-invasive and does not require a biopsy.
These liquid biopsies can be taken pre-, post- or on-treatment,
allowing for continual patient monitoring with the potential to
assess the tumors response to treatment. These biomarkers could
hold particular promise in patients withmetastatic disease, where
monitoring for progression is critical but where repeated biopsy
sampling is often unfeasible due to the location of the lesions.
Studies have investigated the use of blood based biomarkers, such
as carcinoembryonic antigen and carbohydrate antigen 15–3 for
primary diagnosis and the detection of metastatic disease (100–
105), with others examining the correlation between serumHER2
concentration and tumor HER2 status (106–109). Although the
use of blood-based biomarkers to assess tumor pre-treatment
radiosensitivity or on-treatment response to RT has been less
intensively studied, there is a growing interest in the use of
these types of biomarkers for precision RT. Areas of research
currently under investigation include exosomes and circulating
tumor cells (CTCs).
Exosomes are formed from the inward budding of the
membrane of multi-vesicular bodies and are ∼40–100 nm
in diameter. The contents of exosomes are released from
cells via endocytosis through fusion of their membrane with
that of the cell’s plasma membrane. Exosomes have been
shown to contain nucleic acids, proteins, lipids and enzymes
(110). There is increasing evidence that exosomes play roles
in tumorigenesis and cancer progression, including immune
suppression, angiogenesis, cell migration and invasion (111–
115); as a result, their use as liquid biopsy biomarkers
through exosomal profiling is being investigated for disease
diagnosis and therapy efficacy monitoring. The transfer of
exosome contents to local tumor or stromal cells in the tumor
microenvironment, or to a distant site within the body, has
been shown to be a mechanism through which cancer cells
can transmit the malignant phenotype to normal cells and
establish a suitable environment for metastatic colonization
(113). Exosomes transferred from stromal to BC cells can
also contribute to chemotherapy and radiotherapy resistance.
Resistance mechanisms mediated by exosomal transfer are
thought to involve anti-viral and NOTCH3 pathways (116).
Tumor oxygen concentrations at the time of radiation have been
shown to influence cell radiosensitivity (117). When exposed to
a given dose of radiation, cancer cells in low oxygen states can
withstand 2–3 times higher doses than aerobic cells. Known as
the oxygen enhancement effect, the role that oxygen plays in RT
is described through the oxygen fixation hypothesis (118, 119).
Oxygen present at the time of RT can react with radiation-
induced DNA radicals producing permanent DNA damage;
however, in the absence of oxygen this damage can be repaired
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by free radical scavengers such as endogenous thiols (120), giving
these hypoxic cells a significant survival advantage. Hypoxia
leads to the increased production of exosomes (121, 122), with
the transfer of exosomes from stromal to BC cells stimulating
signaling pathways related to radiation resistance (116). The
tumor-associated exosome profile may also give an indication of
the oxygenation status of breast tumors, and therefore could be
used to identify radioresistant tumors (122).
CTCs and circulating tumor DNA are cells or DNA that
have been shed by the tumor into the systemic circulation;
these can be indicators of residual disease following treatment
and are likely to represent an important mechanism through
which a tumor can metastasise (123, 124). CTCs have been
detected in up to 30% of non-metastatic BC patients and their
presence (even just one CTC) has been shown to be prognostic
for recurrence-free survival and overall survival (125–135). CTC
detection is also related to metastasis and poor survival in low-
risk patients with lymph node negative disease who did not
receive adjuvant therapy (133). Data from the National Cancer
Database and SUCCESS (Simultaneous Study of Gemcitabine-
Docetaxel Combination Adjuvant Treatment as well as Extended
Bisphosphonate and Surveillance) clinical trials have been used
to investigate the use of CTC status to predict the benefit of RT
in early stage BC (136). The results suggested that CTC status
could predict the effectiveness of RT and showed that CTC+
patients had improved local recurrence-free survival and disease-
free survival following RT, whereas CTC− patients obtained
no benefit. Furthermore, CTC+ patients that received RT had
improved overall survival compared with CTC+ patients who
did not receive RT. Pooled analysis using both cohorts who
underwent breast-conserving surgery indicated that RT was
associated with longer overall survival in CTC+ patients, but
not in CTC− patients. However, CTC status was not associated
with an overall survival benefit in patients who underwent
mastectomy and RT. Overall, these results suggested that CTC
status may be used as a predictive marker for assessing the
potential benefit from incorporating RT into the treatment of
early stage BC for patients undergoing breast-conserving surgery
(136, 137).
Although circulating tumor biomarkers have the potential to
be used for cancer diagnosis, measuring response to treatment
and monitoring for recurrence, studies evaluating their clinical
usefulness are still limited in number. While advances have
been made in this field, circulating tumor biomarkers in BC
patients are not yet employed for primary diagnosis, largely due
to their low sensitivity and specificity, and also because of a
lack of validation through large prospective trials. Such trials are
essential to fully evaluate their prognostic or predictive potential
in determining tumor radiosensitivity and to enable their use in
the future (138).
BIOMARKERS OF RADIATION-INDUCED
TOXICITY
In contrast to the relatively limited research involving blood-
based biomarkers for tumor radiosensitivity, the use of
circulating biomarkers to assess radiation-induced toxicities has
attracted much greater interest. Like any cancer treatment, RT
has the potential to cause toxic side effects in normal tissues;
these ultimately dictate the total dose that can be delivered
to a patient, which can influence outcome. In BC, radiation-
associated side effects include cardiac and skin toxicities,
fibrosis, lymphedema, secondary cancers, rib fractures and
brachial plexopathy (139). In some studies the combination
of tamoxifen and RT has resulted in an increased risk of
fibrosis, hypothesized to be due to a tamoxifen-induced increase
in TGF-β (140–144). Even with highly conformal intensity-
modulated RT and image-guided RT, which aim to spare
regional organs from radiation exposure, these side effects
can occur in up to 15% of patients and can seriously affect
patients’ physiological and physical quality of life (145, 146).
Taking into account the high survival rate of BC patients,
there is a need to develop tests that can be used either pre-
treatment, or at an early stage of the treatment process, to
predict which patients are at a higher risk of developing
radiation-associated side effects (147). Predicting radiation-
induced toxicity could enable better treatment regimens to
be devised for individual patients in a range of cancer types.
Radiation toxicity is related to treatment schedule (dose and
duration), patient specific factors and genetic factors. With these
in mind, several tests have been proposed to classify individual
patient radiosensitivity based on the induction of DNA damage
and radiation-induced apoptosis, in addition to gene expression
profiles (148).
One area of research that holds promise in predicting the
risk of late radiation-associated toxicity is through assessment
of the radiation-induced initial DNA damage response of
peripheral blood lymphocytes through DNA double strand
break quantification, comet or micronucleus assays (148).
A relationship between high rates of double strand breaks
in peripheral blood lymphocytes and late grade 3 skin and
subcutaneous tissue toxicities in BC patients has suggested
that assessing the initial DNA damage could be useful for
predicting radiation toxicity (149). Unfortunately, various
studies assessing the radiation-induced DNA damage through
other methods have shown both negative (150, 151) and positive
(152–154) associations with radiation toxicity. Additionally,
the clinical usefulness of radiation-induced DNA damage
response assays is yet to be fully determined. Determining
peripheral blood lymphocyte radiation-induced apoptosis
appears to be the most promising assay for determining
radiation toxicity. Studies have shown that radiation-induced
apoptosis increases with higher doses of radiation; however,
elevated levels of radiation-induced apoptosis were associated
with reduced risk of late radiation toxicities (155). In BC
patients, studies have used a combination of DNA damage
assessment and levels of radiation-induced apoptosis to
assess radiation-induced toxicity. Henríquez-Hernández
et al. (156) demonstrated that patients showing lower levels
of initial DNA damage and higher levels of radiation-
induced apoptosis were considered resistant to RT. These
patients were at a lower risk of suffering severe subcutaneous
late toxicities after treatment with high radiation doses.
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Although these results were based on a small number of
patients, it provided evidence that dose escalation can be
achieved in patients that are resistant and tolerant to higher
radiation doses.
There is an association between the dose of radiation received
by the heart and increased risk of heart disease (157–159); as the
dose increases so does the risk of developing heart complications.
Cardiovascular side effects are a major concern for clinicians
treating BC patients with RT (160, 161), especially for left
sided BC or patients with pre-existing cardiovascular disease.
Cardiotoxic effects of RT can be seen for several years after
RT, and increased risk may remain for at least 2 years post-
RT (161). Pericarditis, valvular dysfunction, cardiomyopathy and
coronary artery disease are some of the severe late cardiotoxic
effects seen in up to 30% of BC cases within 5–10 years
following RT (162). Blood biomarkers have been investigated
for their roles in detecting and monitoring cardiotoxicity and
assessing early signs of cardiovascular dysfunction following RT.
Brain natriuretic peptide and its amino terminal fragment are
biomarkers produced by ventricular myocytes, with elevated
blood levels commonly seen in unstable angina, myocardial
infarction and cardiac failure (163). Several studies have shown
that levels of these biomarkers increase after RT, suggesting
that these may be also be biomarkers of early radiation-
induced cardiotoxicity (164–166). Circulating cardiac troponin
I and cardiac troponin T are highly sensitive and specific
biomarkers for cardiac disease and have been shown to be
useful for detecting cardiotoxicity following chemotherapy (167,
168) and, although some studies indicate they do not increase
following RT (165, 169), others show that they do (164,
170, 171). While these traditional cardiac biomarkers are the
most extensively studied for cardiotoxicity following RT, other
blood biomarkers that have been investigated include C-reactive
protein and lipopolysaccharide. C-reactive protein, an acute
phase protein whose expression is related to inflammatory
cytokines, has been proposed as a biomarker of radiation-
associated cytotoxicity as studies have highlighted an association
between elevated C-reactive protein levels and adverse prognosis
in patients with heart failure (172–174). Although Lipshultz
et al. (166) found increased levels of C-reactive protein in
children following treatment for a variety of cancers with
chemotherapy and RT, the majority of studies have failed to
find an association between circulating C-reactive protein levels
and myocardial damage post-chemotherapy (175–177) or RT
(178). Lipopolysaccharide-binding protein has been investigated
as a potential biomarker for lung toxicity after chest RT
(179). In BC, lipopolysaccharide-binding protein concentrations
were observed to increase within 24 h post-RT and remained
elevated 1 month after RT. Raised lipopolysaccharide-binding
protein levels were also correlated with cardiac dysfunction,
which was evaluated up to 3 years following the completion
of RT, suggesting that lipopolysaccharide-binding protein
could be a potentially useful prognostic biomarker of RT-
induced cardiotoxicity (178). Characteristics such as early
detection in the blood and persistent kinetics, in combination
with concentrations being related to toxicity, have made
lipopolysaccharide-binding protein an attractive biomarker for
TABLE 1 | Techniques used for measuring the response of tumors to RT.
Imaging-based methods
Method: Advanced imaging modalities can provide information on tumor size (X-
ray computed tomography, ultrasound, magnetic resonance imaging) and give
an estimation of hypoxia and proliferation heterogeneity within different areas of
a tumor (positron emission tomography). Imaging can be conducted pre-, during
and post-treatment.
Advantages: Non-invasive. Real-time measurements of response can be
obtained. Methods, protocols and criteria for visualizing and assessing changes
in tumor size are already established within the clinic.
Disadvantages: Changes in tumor size can be gradual and slow which may only
be seen towards the end or after the treatment has finished; patients who fail to
respond will initially go undetected. Patient safety concerns over repeat exposure
to radiation and radioisotopes.
Cancer tissue-based biomarkers
Method: Evaluating the expression levels of genes or proteins using biopsy
samples.
Advantages: Pre-treatment biopsies are already taken as part of standard of
care treatment, meaning patients do not require an additional procedure. Protein
assessment using IHC can identify the location of protein expression and
provide information on functional status. Gene signatures may be prognostic and
predictive of responses to RT.
Disadvantages: Invasive. Unable to monitor response to treatment without
further invasive procedures, which can be difficult to obtain and hard to justify.
Some methods of analysis are cost prohibitive. Does not provide real-time
measurements of response.
Blood-based biomarkers
Method: Measuring the presence or expression levels of CTCs or proteins using
liquid biopsy (blood) samples. Samples can be obtained readily pre-, during and
post-treatment.
Advantages: Non-invasive. Real-time measurements of response can be
obtained.
Disadvantages: Low sensitivity and specificity of tests developed to date.
Advantages and disadvantages of each method are provided (IHC,
immunohistochemistry; RT, radiotherapy; CTCs, circulating tumor cells).
clinical use. Other proposed biomarkers include heart-type
fatty acid-binding protein, glycogen phosphorylase isoenzyme
BB, myeloperoxidase and nitric oxide (180). Although these
biomarkers have yet to be used clinically, they could in
the future play key roles in determining which RT patients
may require dose de-escalation, or even the provision of
alternative treatments if BC patients can be classified as
high-risk for developing radiation-induced side effects post-
treatment.
A summary of the techniques used to identify biomarkers
of radiosensitivity that have been described in this paper
is provided in Figure 2 and Table 1. Table 1 also outlines
the specific advantages and disadvantages associated with
each method.
CONCLUSION
Significant advances have been made in the development
of molecular signatures to stratify BC patients for more
personalized targeted and endocrine therapies; however, similar
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FIGURE 2 | Biomarkers of radiotherapy response for breast cancer. An overview of cancer tissue-associated and blood-associated biomarkers of radiotherapy
response that have been developed for breast cancer patients (ER, Estrogen receptor; PgR, Progesterone receptor; HER2, human epidermal growth factor receptor 2).
improvements in the field of personalized RT have yet to
be adopted in the clinic. Technological developments in the
methods used for radiation delivery have allowed radiation
oncologists to accurately conform radiation to the tumor;
however, only limited methods of analyzing response to
treatment are available. To truly achieve personalized RT, we
also need to be able to stratify patient’s pre-treatment based
on individual patient radiosensitivity and through analyzing the
tumor’s response to RT during treatment. Unfortunately, there
are currently no clinically-validated prognostic or predictive
signatures/biomarkers that can reliably classify patients into
those that would benefit the most from RT, those that could
be safely treated with dose escalation or de-escalation, or
those that should be treated without RT. While preliminary
efforts to develop these signatures/biomarkers have been
encouraging, there is still much work to do in order
to refine and validate them. Ultimately, for any of these
tests to be translated into the clinic, studies will need to
demonstrate their accuracy and reproducibility, and perhaps
more importantly, exhibit their utility in improving outcomes
or refining the selection of patients for RT through clinical
trials. While not yet realized, the ongoing development
of these signatures and biomarkers holds much promise;
the linking of these signatures and biomarkers with other
techniques, such as imaging, would help deliver an overall
precision medicine package that could greatly enhance the
effectiveness of RT. There is confidence within the scientific
community that personalized medicine will finally be realized
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for BC patients undergoing radiation treatment in the decades
to come.
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